MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial
Highlights
– MRD-guided strategies did not significantly increase deep remission rates versus standard consolidation in newly diagnosed, transplant-eligible myeloma patients.
– Both MRD-negative and MRD-positive groups showed high rates of MRD negativity at enhanced sensitivity following consolidation, regardless of assignment.
– No new safety signals were reported, and the clinical benefit of MRD-adapted consolidation remains unproven.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.